RIVU SEC-arkiveringar - Rivulet Media Inc- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1079282

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rivulet Media Inc

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

July 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2023 Rivulet Media, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2023 Rivulet Media, Inc.
July 17, 2023	EX-99.1	Signature Page to Follow Exhibit 99.1 July 14, 2023 Rivulet Media, Inc. 1206 East Warner Road, Suite 101-I, Gilbert, Arizona 85296 Attn: Mike Witherill Via email; [email protected] Re: Letter of Intent Dear Sir, This letter of intent summarizes our discussions and reflects our mutual intent to pursue a proposed acquisition, on a stock for stock transaction, by Advanced Voice Recognition Systems, Inc. (“AVOI”), to be re
July 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 14, 2023 Rivulet Media, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 14, 2023 Rivulet Media, Inc.
July 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2023 Rivulet Media, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2023 Rivulet Media, Inc.
July 12, 2023	EX-16.2	July 11, 2023 Exhibit 16.2 July 11, 2023 Securities and Exchange Commission Mail Stop 11-3 450 Fifth Street, N. W. Washington, D.C. 20549 Re; Commission File No. 333-174194 Dear Sirs/Madam, We Have read Item 4.01 of Rivulet Media’s Form 8-K dated July 10, 2023 and we agree with the statements made therein. Yours Truly, /s/ Farber Hass Hurley LLP Oxnard, California
July 25, 2022	EX-10.49	A promissory note executed on June 23, 2022 in favor of Steven Wheeler in the amount of $35,000 Exhibit 10.49 PROMISSORY NOTE $35,000.00 June 23, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of Steven Wheeler, trustee for the Steve and Ann Wheeler Trust (?Holder?) or his designee (?Holder?), the sum of Thirty Five Thousand Dollars ($35,000). 1. Inter
July 25, 2022	EX-10.48	A promissory note executed on June 23, 2022 in favor of Ralph Davis in the amount of $25,000.00 Exhibit 10.48 PROMISSORY NOTE $25,000.00 June 23, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of Ralph Davis (?Holder?) or his designee (?Holder?), the sum of Twenty Five Thousand Dollars ($25,000). 1. Interest. This promissory note (this ?Note?) bears si
July 25, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2022 Rivulet Media, Inc.
July 25, 2022	EX-10.50	A promissory note executed on June 28, 2022 in favor of Ralph Davis in the amount of $10,000.00 Exhibit 10.50 PROMISSORY NOTE $10,000.00 June 28, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of Ralph Davis (?Holder?) or his designee (?Holder?), the sum of Ten Thousand Dollars ($10,000). 1. Interest. This promissory note (this ?Note?) bears simple int
July 11, 2022	EX-10.47	A promissory note executed on June 15, 2022 in favor of Ralph Davis in the amount of $50,000.00 Exhibit 10.47 PROMISSORY NOTE $50,000.00 June 15, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of Ralph Davis (?Holder?) or his designee (?Holder?), the sum of Fifty Thousand Dollars ($50,000). 1. Interest. This promissory note (this ?Note?) bears simple i
July 11, 2022	EX-10.46	A lease agreement between the registrant and the landlord Restart Western Skies, L.P. expiring on June 30 2025. Exhibit 10.46 Lease Agreement This Lease Agreement (the ?Lease?) is entered into as of June 8, 2022, by and between Restart Western Skies, L.P., a Delaware LLC (and any successor or assign, hereafter called ?Landlord?) and Rivulet Media, Inc., a Delaware corporation (hereafter called the ?Tenant?). 1. Description of Premises Landlord hereby leases to Tenant and Tenant leases from Landlord on the t
July 11, 2022	EX-10.42	A promissory note executed on May 26, 2022 in favor of Aaron Klugman in the amount of $50,000.00 Exhibit 10.42 PROMISSORY NOTE $50,000 May 26, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC. , a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of AARON KLUSMAN, an individual residing in Phoenix, AZ, or his designee (?Holder?), the sum of Fifty Thousand Dollars ($50,000). 1. Interest. Interest. This promis
July 11, 2022	EX-10.43	A promissory note executed on June 1, 2022 in favor of Aaron Klugman in the amount of $50,000.00 Exhibit 10.43 PROMISSORY NOTE $50,000 June 1, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC. , a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of AARON KLUSMAN, an individual residing in Phoenix, AZ, or his designee (?Holder?), the sum of Fifty Thousand Dollars ($50,000). 1. Interest. Interest. This promis
July 11, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 26, 2022 Rivulet Media, Inc.
July 11, 2022	EX-10.45	A promissory note executed on June 8, 2022 in favor of David Crosser in the amount of $60,000.00 Exhibit 10.45 PROMISSORY NOTE $60,000.00 June 8, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of Daniel Crosser (“Holder”) or his designee (“Holder”), the sum of Sixty Thousand Dollars ($60,000). 1. Interest. This promissory note (this “Note”) bears simple
July 11, 2022	EX-10.44	A promissory note executed on June 1, 2022 in favor of David Crosser in the amount of $20,000.00 Exhibit 10.44 PROMISSORY NOTE $20,000.00 June 1, 2022 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of Daniel Crosser (?Holder?) or his designee (?Holder?), the sum of Twenty Thousand Dollars ($20,000). 1. Interest. This promissory note (this ?Note?) bears simpl
May 31, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 24, 2022 Rivulet Media, Inc.
May 18, 2022	EX-10.1	Settlement Agreement between the Company and Geneva Roth Remark Holdings, Inc., dated February 8, 2022. Exhibit 10.1 Geneva Roth Remark Holdings, Inc. February 8, 2022 Email: [email protected] [email protected] RIVULET MEDIA INC. 1206 East Warner Road, Suite 101-I Gilbert, Arizona 85296 Attn: Rick Gean, Interim Chief Financial Officer Michael Witherill, President RE: GENEVA ROTH REMARK HOLDINGS, INC. ? Convertible Promissory Note Ladies and Gentlemen: With respect to the three (3) Convertible
May 18, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2022 Rivulet Media, Inc.
May 18, 2022	EX-10.3	Mutual Release between the Company and Geneva Roth Remark Holdings, Inc., dated April 27, 2022. Exhibit 10.3 MUTUAL RELEASE AND AGREEMENT This Mutual Release and Agreement (the “Agreement”) dated as of April 27, 2022, is entered into by and between RIVULET MEDIA INC. (“RIVULET”), and GENEVA ROTH REMARK HOLDINGS, INC. (“GENEVA” and together with RIVULET, collectively, jointly and severally, referred to herein as the “Parties” or singularly a “Party”). WHEREAS, RIVULET has issued to GENEVA thr
May 18, 2022	EX-10.2	Amendment to Settlement Agreement between the Company and Geneva Roth Remark Holdings, Inc., dated April 19, 2022. Exhibit 10.2 Geneva Roth Remark Holdings, Inc. April 19, 2022 Email: [email protected] [email protected] RIVULET MEDIA INC. 1206 East Warner Road, Suite 101-I Gilbert, Arizona 85296 Attn: Rick Gean, Interim Chief Financial Officer Michael Witherill, President RE: GENEVA ROTH REMARK HOLDINGS, INC. ? Convertible Promissory Ladies and Gentlemen: As we discussed with respect to the settlement ag
May 13, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended July 31, 2021 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No.
May 13, 2022	EX-21.1	Subsidiaries of the Company. EX-21.1 2 ex21-1.htm SUBSIDIARIES OF THE COMPANY Exhibit 21.1 Subsidiaries of the Company Rivulet Films, Inc. – Delaware Maughan Music, Inc. – Delaware Storyland Animation Studios, LLC – Arizona Eventide Media, LLC – Arizona Borderline Productions, LLC – Arizona (a subsidiary of Rivulet Films, Inc.) PBP Productions, LLC – Arizona (a subsidiary of Rivulet Films, Inc.) Mistress Movie, LLC – Arizona
March 24, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2022 Rivulet Media, Inc.
February 17, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 8, 2022 Rivulet Media, Inc.
February 17, 2022	EX-10.1	Settlement Agreement between Rivulet Media, Inc. and Geneva Roth Remark Holdings, Inc., dated February 8, 2022. Exhibit 10.1 Geneva Roth Remark Holdings, Inc. February 8, 2022 Email: [email protected] [email protected] RIVULET MEDIA INC. 1206 East Warner Road, Suite 101-I Gilbert, Arizona 85296 Attn: Rick Gean, Interim Chief Financial Officer Michael Witherill, President RE: GENEVA ROTH REMARK HOLDINGS, INC. ? Convertible Promissory Note Ladies and Gentlemen: With respect to the three (3) Convertible
January 31, 2022	EX-10.1	Form of Amendment to Promissory Note, incorporated by reference to Exhibit 10.1 the Form 8-K filed on February 26, 2021. Exhibit 10.1 PROMISSORY NOTE $ , 20 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of (?Holder?) or his designee, the sum of ($). 1. Interest. This promissory note (this ?Note?) bears simple interest at the rate of ten percent (10%) per annum. 2. Payments. The en
January 31, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2021 Rivulet Media, Inc.
January 10, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2021 Rivulet Media, Inc.
January 10, 2022	8-K	Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2022 Rivulet Media, Inc.
November 29, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2021 Rivulet Media, Inc.
November 29, 2021	EX-10.4	Form of Multiple Advance Promissory Note. EX-10.4 5 ex10-4.htm FORM OF MULTIPLE ADVANCE PROMISSORY NOTE. Exhibit 10.4 MULTIPLE ADVANCE PROMISSORY NOTE $ (the “Principal Amount”) November 23, 2021 This MULTIPLE ADVANCE PROMISSORY NOTE (the “Note”) is made by and between RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Road Suite 101-I, Gilbert, Arizona 85296 (“Maker”), and , an individual with an address of (“H
November 29, 2021	EX-10.9	Loan Agreement and Promissory Note between the Company and Mr. Witherill dated September 27, 2021. EX-10.9 10 ex10-9.htm LOAN AGREEMENT AND PROMISSORY NOTE BETWEEN THE COMPANY AND MR. WITHERILL DATED SEPTEMBER 27, 2021. Exhibit 10.9 LOAN AGREEMENT AND PROMISSORY NOTE $1,400,000 (the “Principal Amount”) September 27, 2021 FOR VALUE RECEIVED, Michael Witherill, an individual with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), promises to pay to Rivulet Media, Inc., a De
November 29, 2021	EX-10.11	Loan Agreement and Promissory Note between the Company and Mr. Larson dated November 9, 2021. EX-10.11 12 ex10-11.htm LOAN AGREEMENT AND PROMISSORY NOTE BETWEEN THE COMPANY AND MR. LARSON DATED NOVEMBER 9, 2021. Exhibit 10.11 LOAN AGREEMENT AND PROMISSORY NOTE $793,000 (the “Principal Amount”) November 9, 2021 FOR VALUE RECEIVED, Damian Larson, an individual with an address of 6611 E. Mayo Blvd. #2059, Phoenix, AZ 85054 (“Maker”), promises to pay to Rivulet Media, Inc., a Delaware corporat
November 29, 2021	EX-10.10	Stock Sale Agreement between the Company and Mr. Larson dated November 9, 2021. EX-10.10 11 ex10-10.htm STOCK SALE AGREEMENT BETWEEN THE COMPANY AND MR. LARSON DATED NOVEMBER 9, 2021. Exhibit 10.10 STOCK SALE AGREEMENT This Stock Sale Agreement (this “Agreement”) is dated November 9, 2021 (the “Effective Date”), between Rivulet Media, Inc., a Delaware corporation with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Seller”), and Damian Larson, an individual w
November 29, 2021	EX-10.12	Termination Agreement between the Company and Mr. Witherill dated November 8, 2021. EX-10.12 13 ex10-12.htm TERMINATION AGREEMENT BETWEEN THE COMPANY AND MR. WITHERILL DATED NOVEMBER 8, 2021. Exhibit 10.12 TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (this “Termination Agreement”) is entered into as of November 8, 2021 (the “Effective Date”), by and between Michael Witherill and Rivulet Media, Inc. (the “Company”). The foregoing may each be referred to as a “Party” and collec
November 29, 2021	EX-10.7	Negotiable Secured Promissory Note between Rivulet Films, Inc. and Topps, LLC dated September 16, 2021. EX-10.7 8 ex10-7.htm NEGOTIABLE SECURED PROMISSORY NOTE BETWEEN RIVULET FILMS, INC. AND TOPPS, LLC DATED SEPTEMBER 16, 2021. Exhibit 10.7 NEGOTOIABLE SECURED PROMISSORY NOTE $600,000.00 September 16, 2021 Phoenix, AZ For value received RIVULET FILMS, INC., a Delaware corporation, (“Payor”) hereby promises to pay to TOPPS, LLC, an Arizona limited liability company and/or Nominee (“Holder”) at 11575
November 29, 2021	EX-10.1	Form of Promissory Note. EX-10.1 2 ex10-1.htm FORM OF PROMISSORY NOTE. Exhibit 10.1 PROMISSORY NOTE $ , 2021 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of with an address of (“Holder”), the sum of ($), with such amount payable to Holder at the address set forth above, or at such othe
November 29, 2021	EX-10.3	Form of Series A Convertible Promissory Note. EX-10.3 4 ex10-3.htm FORM OF SERIES A CONVERTIBLE PROMISSORY NOTE. Exhibit 10.3 NEITHER THIS PROMISSORY NOTE (THIS “NOTE”) NOR THE SECURITIES THAT ARE ISSUABLE UPON CONVERSION HEREOF (COLLECTIVELY, THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENC
November 29, 2021	EX-10.5	Commercial Loan Agreement between Rivulet Films, Inc. and Topps, LLC dated September 16, 2021. Exhibit 10.5 COMMERCIAL LOAN AGREEMENT This COMMERCIAL LOAN AGREEMENT (the ?Agreement?) is made and entered into effective as of this 16th day of September 2021 (?Effective Date?), by and between TOPPS, LLC, an Arizona limited liability company (?Lender?) and RIVULET FILMS, INC., a Delaware corporation (?Borrower?). RECITALS: A. Borrower has requested of Lender a loan in the aggregate principal am
November 29, 2021	EX-10.6	Collateral Security Agreement between Rivulet Films, Inc. and Topps, LLC dated September 16, 2021. EX-10.6 7 ex10-6.htm COLLATERAL SECURITY AGREEMENT BETWEEN RIVULET FILMS, INC. AND TOPPS, LLC DATED SEPTEMBER 16, 2021 Exhibit 10.6 COLLATERAL SECURITY AGREEMENT THIS COLLATERAL SECURITY AGREEMENT (“Agreement”) is made this 16th day of September, 2021, between RIVULET FILMS, INC., a Delaware corporation, and its wholly owned subsidiaries: PBP PRODUCTIONS, LLC, an Arizona limited liability company
November 29, 2021	EX-10.2	Form of Convertible Promissory Note. EX-10.2 3 ex10-2.htm FORM OF CONVERTIBLE PROMISSORY NOTE. Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE A
November 29, 2021	EX-10.8	Stock Sale Agreement between the Company and Mr. Witherill dated September 27, 2021. EX-10.8 9 ex10-8.htm STOCK SALE AGREEMENT BETWEEN THE COMPANY AND MR. WITHERILL DATED SEPTEMBER 27, 2021. Exhibit 10.8 STOCK SALE AGREEMENT This Stock Sale Agreement (this “Agreement”) is dated September 27, 2021 (the “Effective Date”), between Rivulet Media, Inc., a Delaware corporation with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Seller”), and Michael Witherill, an indiv
October 29, 2021	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-32201 CUSIP NUMBER 769666108 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period ended: July 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transiti
October 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2021 Rivulet Media, Inc.
June 21, 2021	EX-10.8	Promissory Note dated June 2, 2021. EX-10.8 2 ex10-8.htm PROMISSORY NOTE DATED JUNE 2, 2021 Exhibit 10.8 PROMISSORY NOTE $90,933.12 June 2, 2021 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of LAWRENCE M. SILVER, with an address of 200 East Palmetto Park Road #514, Boca Raton, FL 33432 (“Holder”)
June 21, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-32201 RIVULET MEDIA, INC.
June 15, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-32201 CUSIP NUMBER 769666108 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period ended: April 30, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transit
May 10, 2021	EX-10.1	Promissory Note dated May 7, 2021. EX-10.1 2 ex10-1.htm PROMISSORY NOTE DATED MAY 7, 2021. Exhibit 10.1 PROMISSORY NOTE $70,000 May 7, 2021 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of CROSS ENTERTAINMENT, L.L.C., an Arizona limited liability company with an address of 2700 N. Central Avenue,
May 10, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 form8-k.htm RIVULET MEDIA, INC. 8-K United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 29, 2021 Rivulet Media, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 0
May 10, 2021	EX-10.1	Amendment to Promissory Note dated April 29, 2021. EX-10.1 2 ex10-1.htm AMENDMENT TO PROMISSORY NOTE DATED APRIL 29, 2021. Exhibit 10.1 AMENDMENT TO PROMISSORY NOTE This Amendment to Promissory Note (this “Amendment”) is effective as of April 29, 2021 and is by and between Rivulet Media, Inc., a Delaware corporation (“Maker”) and Daniel D. Crosser (“Holder”). Capitalized terms not otherwise defined herein have the meanings given to them in the Not
May 10, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2021 Rivulet Media, Inc.
May 4, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Rivulet Media, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 769666 108 (CUSIP Number) Law
April 22, 2021	EX-10.1	Promissory Note dated April 20, 2021. EX-10.1 2 ex10-1.htm PROMISSORY NOTE DATED APRIL 20, 2021 Exhibit 10.1 PROMISSORY NOTE $1,500 April 20, 2021 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of CROSS ENTERTAINMENT, L.L.C., an Arizona limited liability company with an address of 2700 N. Central Ave
April 22, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 20, 2021 Rivulet Media, Inc.
March 22, 2021	EX-10.11	Amendment to Life Story Rights Agreement dated June 1, 2020. EX-10.11 2 ex10-11.htm AMENDMENT TO LIFE STORY RIGHTS AGREEMENT DATED JUNE 1, 2020 Exhibit 10.11 June 1, 2020 LIFE STORY RIGHTS AMENDED AGREEMENT THIS AMENDED AGREEMENT, which is effective on June 1, 2020, is made between RIVULET MEDIA, INC., a Delaware corporation, and/or it’s assignee (“Producer”) and Joseph M. Arpaio (“Owner”) concerning the Owner’s life story. The following amended terms are i
March 22, 2021	10-Q	Quarterly Report - RIVULET MEDIA, INC. 10-Q 10-Q 1 form-10q.htm RIVULET MEDIA, INC. 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-32201 RIVULET ME
March 22, 2021	EX-10.12	Amendment to Employment Agreement between Rivulet Films, Inc., Rivulet Media, Inc., Paris Film, Inc. and Rob Paris dated March 1, 2021. EX-10.12 3 ex10-12.htm AMENDMENT TO EMPLOYMENT AGREEMENT BETWEEN RIVULET FILMS, INC., RIVULET MEDIA, INC., PARIS FILM, INC. AND ROB PARIS DATED MARCH 1, 2021 Exhibit 10.12 MARCH 1, 2021 ROB PARIS AMENDED EMPLOYMENT AGREEMENT THIS AMENDED AGREEMENT, WHICH IS EFFECTIVE ON MARCH 1, 2021, IS MADE BETWEEN RIVULET FILMS INC, A DELAWARE CORPORATION, AND ROB PARIS OF PARIS FILMS INC. THE FOLLOWING AMENDED
March 17, 2021	NT 10-Q	- RIVULET MEDIA, INC. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-32201 CUSIP NUMBER 769666108 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR ? Form N-SCR For Period ended: January 31, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Trans
March 16, 2021	SC 13D	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Rivulet Media, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 769666 108 (CUSIP Number) Lawre
March 15, 2021	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Rivulet Media, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 769666 108 (CUSIP Number) Dan
March 3, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 11, 2021 Rivulet Media, Inc.
March 3, 2021	EX-10.1	Promissory Note EX-10.1 2 ex10-1.htm PROMISSORY NOTE Exhibit 10.1 PROMISSORY NOTE $100,000 February 11, 2021 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of LAWRENCE M. SILVER, an individual with an address of 55 E. Erie St. #2505, Chicago IL, 60611 (“Holder”), the sum of One
March 2, 2021	EX-10.1	Form of Amendment to Promissory Note. Exhibit 10.1 AMENDMENT TO PROMISSORY NOTE This Amendment to Promissory Note (this ?Amendment?) is effective as of , 2021 and is by and between (?Maker?) and (?Holder?). Capitalized terms not otherwise defined herein have the meanings given to them in the Note (as defined below). WHEREAS, Maker executed a Promissory Note dated , 20, payable to Holder in the original principal amount of $ (the ?Note
March 2, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2021 Rivulet Media, Inc.
February 26, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8-k.htm RIVULET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 31, 2021 Rivulet Media, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation)
February 26, 2021	EX-10.1	Form of Amendment to Promissory Note Exhibit 10.1 AMENDMENT TO PROMISSORY NOTE This Amendment to Promissory Note (this ?Amendment?) is effective as of , 2021 and is by and between Rivulet Media, Inc., a Delaware corporation (?Maker?) and (?Holder?). Capitalized terms not otherwise defined herein have the meanings given to them in the Note (as defined below). WHEREAS, Maker executed a Promissory Note dated , 20, payable to Holder in t
February 10, 2021	EX-10.1	Promissory Note dated January 29, 2021. Exhibit 10.1 PROMISSORY NOTE $85,000 January 29, 2021 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of CROSS ENTERTAINMENT, L.L.C., an Arizona limited liability company with an address of 2700 N. Central Avenue, Ste. 950, Phoenix, AZ 85004 (“Holder”), the sum of
February 10, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2021 Rivulet Media, Inc.
January 28, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2020 Rivulet Media, Inc.
January 28, 2021	EX-10.2	Amended to Employment Agreement between Rivulet Media, Inc. and Michael J. Witherill, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on January 28, 2021. Exhibit 10.2 AMENDMENT TO EMPLOYMENT AGREEMENT This Amendment to Employment Agreement (this “Amendment”) is by and between Michael J. Witherill (“Executive”) and Rivulet Media, Inc., a Delaware corporation (the “Company”). WHEREAS, the parties entered into that certain Employment Agreement dated August 12, 2020 (the “Employment Agreement”); and WHEREAS, the parties desire to amend the Employment A
January 28, 2021	EX-10.1	Amendment to Employment Agreement Exhibit 10.1 PROMISSORY NOTE $ , 2020 FOR VALUE RECEIVED, MISTRESS MOVIE LLC, an Arizona limited liability company with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of CROSS ENTERTAINMENT, L.L.C., an Arizona limited liability company with an address of 2700 N. Central Avenue, Ste. 950, Phoenix, AZ 85004 (“Holder”), the sum of Fi
January 14, 2021	EX-10.1	Form of Promissory Note. Exhibit 10.1 PROMISSORY NOTE $ , 20 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of with an address of (“Holder”), the sum of ($), with such amount payable to Holder at the address set forth above, or at such other place as Holder may designate. 1. No Interest.
January 14, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits - RIVULET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2020 Rivulet Media, Inc.
January 4, 2021	EX-10.3	Form of Subscription Agreement for Common Stock. EX-10.3 4 exhibit10-3.htm FORM OF SUBSCRIPTION AGREEMENT FOR COMMON STOCK. EXHIBIT 10.3 SUBSCRIPTION AGREEMENT RIVULET MEDIA, INC. Rivulet Media, Inc. 1206 E. Warner Rd, Suite 101-I Gilbert, Arizona 85296 Attn: Michael Witherill Re: Purchase of Rivulet Media, Inc. Common Shares Gentlemen: The undersigned (the “Purchaser”) hereby subscribes to purchase the number of shares of Common Stock, $0.0001
January 4, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits 8-K 1 rivulet8k.htm RIVULET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2020 Rivulet Media, Inc. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporati
January 4, 2021	EX-10.2	Form of Amended Convertible Promissory Note, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on January 4, 2021. EXHIBIT 10.2 NEITHER THIS PROMISSORY NOTE (THIS “NOTE”) NOR THE SECURITIES THAT ARE ISSUABLE UPON CONVERSION HEREOF (COLLECTIVELY, THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UND
January 4, 2021	EX-10.1	Form of Subscription Agreement for Amended Note. EXHIBIT 10.1 SUBSCRIPTION AGREEMENT RIVULET MEDIA, INC. Rivulet Media, Inc. 1206 E. Warner Rd, Suite 101-I Gilbert, Arizona 85296 Attn: Michael Witherill Re: Purchase of Rivulet Media, Inc. Series A Convertible Promissory Notes Gentlemen: The undersigned (“Purchaser”) hereby subscribes to purchase the amount of Series A convertible promissory notes (“Notes”) of Rivulet Media, Inc., a Delaware corp
December 15, 2020	10-Q	Quarterly Report - RIVULET MEDIA, INC. 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2020 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-32201 RIVULET MEDIA, INC. (Exact name of registrant as specif
December 10, 2020	8-K	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 10, 2020 Rivulet Media, Inc.
December 10, 2020	EX-10.1	Promissory Note dated December 10, 2020. EXHIBIT 10.1 PROMISSORY NOTE $160,000 December 10, 2020 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (?Maker?), agrees and promises to pay to the order of DANIEL D. CROSSER, and individual with an address of 225 12th Street, Manhattan Beach, CA 90266 (?Holder?), the sum of One Hundred Sixty Thousand Dollars ($1
December 3, 2020	8-K	Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits - RIVLET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2020 Rivulet Media, Inc.
December 3, 2020	EX-10.1	Promissory Note dated November 10, 2020. EX-10.1 2 exhibit10-1.htm PROMISSORY NOTE DATED NOVEMBER 10, 2020 EXHIBIT 10.1 PROMISSORY NOTE $200,000 November 10, 2020 FOR VALUE RECEIVED, RIVULET MEDIA, INC., a Delaware corporation with an address of 1206 E. Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Maker”), agrees and promises to pay to the order of DANIEL D. CROSSER, and individual with an address of 225 12th Street, Manhattan Beach, CA 9
November 12, 2020	EX-10.10	2020 Equity Incentive Plan Exhibit 10.10 RIVULET MEDIA, INC. 2020 EQUITY INCENTIVE PLAN 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Rivulet Media, Inc. 2020 Equity Incentive Plan (the ?Plan?). The purposes of the Plan are to (a) enable Rivulet Media, Inc., a Delaware corporation (the ?Company?), and any Affiliate to attract and retain the types of Employees, Consultants and Directors who will
November 12, 2020	EX-4.1	Form of Stock Option Agreement Exhibit 4.1 RIVULET MEDIA, INC. STOCK OPTION AGREEMENT Rivulet Media, Inc. has granted to the individual (the “Participant”) named in the Notice of Grant of Stock Option (the “Notice”) to which this Stock Option Agreement (the “Option Agreement”) is attached an option (the “Option”) to purchase certain shares of Common Stock upon the terms and conditions set forth in the Notice and this Option Agr
November 12, 2020	EX-21.1	Subsidiaries of the Company Exhibit 21.1 Subsidiaries of the Company Rivulet Films, Inc. Maughan Music, Inc.
November 12, 2020	EX-10.14	Promissory Note dated October 29, 2020, made by Rivulet Media, Inc. to Daniel Crosser. Exhibit 10.14 PROMISSORY NOTE $100,000.00 Gilbert, Arizona October 29, 2020 For value received, RIVULET MEDIA, INC., a Delaware corporation (the ?Borrower?), promises to pay to the order of DAN CROSSER (the ?Lender?), the principal amount of ONE HUNDRED THOUSAND AND NO/100THS DOLLARS ($100,000.00) pursuant the terms of this Promissory Note (the ?Note?), with interest thereon as provided below. 1.
November 12, 2020	10-K	United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K United States Securities and Exchange Commission Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended July 31, 2020 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-32201 Rivulet Media, Inc. (Exact name o
November 12, 2020	SC 13D/A	RIVU / RIVULET MEDIA INC / Witherill Michael J - RIVULET MEDIA SC 13DA Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Rivulet Media, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 769666108 (CUSIP Number) Mike
November 4, 2020	8-K	- RIVULET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 29, 2020 RIVULET MEDIA, INC.
October 30, 2020	NT 10-K	- RIVULET MEDIA, INC. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 000-32201 CUSIP NUMBER 769666108 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-SCR For Period ended: July 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti
October 30, 2020	EX-10.3	Amendment to Employment Agreement, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on January 28, 2021. Exhibit 10.3 GUARANTY This Guaranty is dated as of October 27, 2020, and made by the undersigned, Michael Witherill, Aaron Klusman, and Rivulet Media, Inc., a Delaware corporation (together “Guarantors”), to and in favor of Lawrence M. Silver (“Lender”). Rivulet Films, Inc., a Delaware corporation (“Borrower”), has executed and delivered a Multiple Advance Promissory Note of even date hereof in th
October 30, 2020	EX-10.1	Multiple Advance Promissory Note, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on October 30, 2020. Exhibit 10.1 MULTIPLE ADVANCE PROMISSORY NOTE $1,000,000 (the “Principal Amount”) October 26, 2020 FOR VALUE RECEIVED, Rivulet Films, Inc., a Delaware corporation with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Company”), promises to pay to Lawrence M. Silver, an individual with an address of 55 E. Erie St. #2505, Chicago IL, 60611, or his assignee, (“Lender”), the Principal
October 30, 2020	EX-10.2	Security Agreement, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on October 30, 2020. Exhibit 10.2 SECURITY AGREEMENT THIS SECURITY AGREEMENT, dated October 26, 2020 (as amended, supplemented, or otherwise modified from time to time, this “Agreement”), is made by and between Rivulet Films, Inc., a Delaware corporation with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Grantor”), and Lawrence M. Silver, an individual with an address of 55 E. Erie St. #2505, Chicag
October 30, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2020 Rivulet Media, Inc.
October 22, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits - RIVULET MEDIA, INC. 8-K United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2020 Rivulet Media, Inc.
October 22, 2020	EX-10.3	Form of Subscription Agreement for Common Stock, incorporated by reference to Exhibit 10.3 of the Form 8-K filed on October 22, 2020. Exhibit 10.3 SUBSCRIPTION AGREEMENT RIVULET MEDIA, INC. Rivulet Media, Inc. 1206 E. Warner Rd, Suite 101-I Gilbert, Arizona 85296 Attn: Michael Witherill Re: Purchase of Rivulet Media, Inc. Common Shares Gentlemen: The undersigned (the “Purchaser”) hereby subscribes to purchase the number of shares of Common Stock, $0.0001 par value per share, of Rivulet Media, Inc., a Delaware corporation (the “C
October 22, 2020	EX-10.2	Form of Amended Note, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on January 4, 2021. EX-10.2 3 ex10-2.htm FORM OF CONVERTIBLE PROMISSORY NOTE Exhibit 10.2 NEITHER THIS PROMISSORY NOTE (THIS “NOTE”) NOR THE SECURITIES THAT ARE ISSUABLE UPON CONVERSION HEREOF (COLLECTIVELY, THE “SECURITIES”) HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED: (I) IN THE ABSENCE OF (A) A
October 22, 2020	EX-10.1	Form of Subscription Agreement for Amended Convertible Promissory Note, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on January 4, 2021. EX-10.1 2 ex10-1.htm FORM OF SUBSCRIPTION AGREEMENT FOR CONVERTIBLE PROMISSORY NOTE. Exhibit 10.1 SUBSCRIPTION AGREEMENT RIVULET MEDIA, INC. Rivulet Media, Inc. 1206 E. Warner Rd, Suite 101-I Gilbert, Arizona 85296 Attn: Michael Witherill Re: Purchase of Rivulet Media, Inc. Series A Convertible Promissory Notes Gentlemen: The undersigned (“Purchaser”) hereby subscribes to purchase the amount of Se
September 24, 2020	EX-99.1	Rivulet Media Revises OTC Stock Symbol to RIVU EXHIBIT 99.1 Rivulet Media Revises OTC Stock Symbol to RIVU Gilbert, AZ— (Sept. 21, 2020) Rivulet Media, an entertainment business innovator in film, TV and music production, announced today that the Financial Industry Regulatory Authority ("FINRA"), has approved a change in the Company's stock symbol on the OTC Markets. Effective September 21, 2020, the Company's common shares will begin trading
September 24, 2020	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2020 Rivulet Media, Inc.
August 27, 2020	8-K	- RIVULET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 25, 2020 Rivulet Media, Inc.
August 26, 2020	SC 13D	BMSN / Bio-Matrix Scientific Group, Inc. / CROSSER DANIEL DEAN - RIVULET MEDIA, INC. SC 13D Activist Investment SC 13D 1 schedule-13d.htm RIVULET MEDIA, INC. SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Rivulet Media, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of
August 17, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - RIVULET MEDIA, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2020 Rivulet Media, Inc.
August 17, 2020	EX-10.1	Employment Agreement between Rivulet Media, Inc. and Michael J. Witherill executed August 12, 2020, incorporated by reference to Exhibit 10.1 of the Form 8-K filed on August 17, 2020. EXHIBIT 10.1 July 20, 2020 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made in the State of Arizona by and between Michael J. Witherill (“Executive”) and Rivulet Media, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company is engaged in the film and music business producing full-length films, documentaries, musicals and popular music for distribution nationally and
August 17, 2020	EX-10.2	Employment Agreement between Rivulet Media, Inc. and Aaron Klusman executed August 14, 2020, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on August 17, 2020. EXHIBIT 10.2 July 20, 2020 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made in the State of Arizona by and between Aaron Klusman (“Executive”) and Rivulet Media, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company is engaged in the film and music business producing full-length films, documentaries, musicals and popular music for distribution nationally and intern
July 31, 2020	8-K/A	Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No.
July 13, 2020	SC 13D/A	BMSN / Bio-Matrix Scientific Group, Inc. / Witherill Michael J - RIVULET MEDIA, INC. SCHEDULE 13D/A, AMENDMENT NO. 1 Activist Investment SC 13D/A 1 rivuletsc13da.htm RIVULET MEDIA, INC. SCHEDULE 13D/A, AMENDMENT NO. 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Rivulet Media, Inc. (Name of Issuer) Common Stock, par val
July 9, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 2, 2020 Rivulet Media, Inc.
July 7, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2020 Rivulet Media, Inc.
July 7, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2020 Rivulet Media, Inc.
July 7, 2020	10-Q/A	Quarterly Report - RIVULET MEDIA, INC. 10-Q/A, AMENDMENT NO. 1 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-32201 Rivulet Medi
July 1, 2020	EX-10.2	Assignment of Promissory Note dated effective as of April 16, 2020. Exhibit 10.2 ASSIGNMENT OF PROMISSORY NOTE THIS ASSIGNMENT OF PROMISSORY NOTE (this “Assignment”) is effective as of April 16, 2020, and is by and among RIVULET FILMS LLC, an Arizona limited liability company (“Assignor”), and RIVULET MEDIA, INC., a Delaware corporation (“Assignee” and together with Assignor, the “Parties”). RECITALS A. Blue Scout Enterprises LLC, an Arizona limited liability comp
July 1, 2020	EX-10.1	Promissory Note dated April 7, 2020, made by Blue Scout Enterprises payable to Rivulet Films LLC. Exhibit 10.1 PROMISSORY NOTE $550,000.00 February 11, 2020 FOR VALUE RECEIVED, BLUE SCOUT ENTERPRISES LLC, an Arizona limited liability company with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (the “Company”), agrees and promises to pay to the order of RIVULET FILMS LLC, an Arizona limited liability company with an address of 1206 E Warner Rd, Suite 101-I, Gilbert, AZ 85296 (“Ho
July 1, 2020	10-Q	Quarterly Report - RIVULET MEDIA, INC. 10-Q 10-Q 1 form-10q.htm RIVULET MEDIA, INC. 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu
June 29, 2020	8-K	Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2020 Rivulet Media, Inc.
June 29, 2020	EX-99.1	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Members of Rivulet Films LLC Opinion on the Financial Statements We have audited the accompanying balance sheet of Rivulet Films LLC (the Company) as of March 31, 2020, and the related statements of operations, members’ equity, and cash flows for the year ended March 31, 2020, and the related notes (
June 29, 2020	SC 13D	BMSN / Bio-Matrix Scientific Group, Inc. / Witherill Michael J - RIVULET MEDIA, INC. SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.) Rivulet Media, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09065C502 (CUSIP Number) Mike W
June 10, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2020 Rivulet Media, Inc.
June 5, 2020	EX-2.1	Agreement and Plan of Merger by and among Rivulet Media, Inc., Maughan Music, Inc., and Maughan Music Group LLC, dated May 28, 2020, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on June 5, 2020. EX-2.1 2 exhibit2-1.htm AGREEMENT AND PLAN OF MERGER BY AND AMONG RIVULET MEDIA, INC., MAUGHAN MUSIC, INC., AND MAUGHAN MUSIC GROUP LLC, DATED MAY 26, 2020 EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER by and among RIVULET MEDIA, INC., a Delaware corporation, MAUGHAN MUSIC, INC., a Delaware corporation, and MAUGHAN MUSIC GROUP LLC, an Arizona limited liability company Dated as of May 28, 2020 TABLE OF
June 5, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2020 Rivulet Media, Inc.
May 28, 2020	EX-99.1	Rivulet Films Announces Production Plans for TV Docu-Series About America’s Toughest Sheriff, Joe Arpaio EXHIBIT 99.1 Rivulet Films Announces Production Plans for TV Docu-Series About America’s Toughest Sheriff, Joe Arpaio May 26, 2020 (Gilbert, AZ)…Rivulet Films announces the start of production with filming to begin June 2, 2020 for a new docu-series, named (TBD), based on the life experiences of “America’s Toughest Sheriff” Joe Arpaio who served as the 34th Sheriff of Maricopa County, Arizona for
May 28, 2020	EX-10.2	Employment Agreement between Rivulet Films, Inc., Rivulet Media, Inc., Paris Film, Inc., and Rob Paris, dated May 27, 2020, incorporated by reference to Exhibit 10.2 of the Form 8-K filed on May 28, 2020. EXHIBIT 10.2 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the "Agreement"), dated as of May 27, 2020 (the "Effective Date") is made by and between Rivulet Films, Inc., a Delaware corporation (the "Company"), Rivulet Media, Inc., a Delaware corporation (the "Parent") and Paris Film, Inc. with regard to the cash compensation and Rob Paris (individually) with regard to the stock grant (collectivel
May 28, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2020 Rivulet Media, Inc.
May 28, 2020	EX-10.1	Life Story Rights Agreement between Rivulet Media, Inc. and Joseph M. Arpaio, dated May 20, 2020. EXHIBIT 10.1 May 20, 2020 LIFE STORY RIGHTS AGREEMENT THIS AGREEMENT, which is effective on May 20, 2020, is made by and between RIVULET MEDIA, INC., a Delaware corporation, and/or its assignee ("Producer") and Joseph M. Arpaio ("Owner") concerning the Owner's life story. (Owner and Producer shall be referred to hereinafter collectively as the "Parties.") The following terms and conditions shall a
May 1, 2020	DEF 14C	Amended and Restated Certificate of Incorporation of Bio-Matrix Scientific Group, Inc., incorporated by reference to Exhibit A of the Schedule 14C filed on May 1, 2020. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14C Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement BIO-MATRIX SCIENTIFIC GROUP, INC. (Name of Regis
April 22, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 16, 2020 Bio-Matrix Scientific Group, Inc.
April 22, 2020	EX-3.1	Amended and Restated Bylaws, incorporated by reference to Exhibit 3.1 of the Form 8-K filed on April 22, 2020. EX-3.1 2 exhibit3-1.htm AMENDED AND RESTATED BYLAWS OF BIO-MATRIX SCIENTIFIC GROUP, INC. EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS of Bio-Matrix Scientific Group, Inc. A Delaware Corporation (Effective as of April 16, 2020) ARTICLE 1 CERTAIN DEFINITIONS 1.1 Definitions. As used in these Bylaws, unless the context otherwise requires, the term: a. “Assistant Secretary” means an Assistant Secretary of
April 22, 2020	EX-16.1	Letter to Securities and Exchange Commission from BF Borgers CPA PC, dated April 21, 2020. [BORGERS LETTERHEAD] April 21, 2020 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.
April 13, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 8, 2020 Bio-Matrix Scientific Group, Inc.
April 13, 2020	EX-99.1	Rivulet Films Merges with Bio-Matrix Scientific Group, Inc. NEW Rivulet Media to Fund Film Productions Using Proprietary Financing Model Rivulet Films Merges with Bio-Matrix Scientific Group, Inc. NEW Rivulet Media to Fund Film Productions Using Proprietary Financing Model April 9, 2020 - Gilbert, AZ - Rivulet Films’ Executives Aaron Klusman and Mike Witherill are announcing a merger with publicly traded Bio-Matrix Scientific Group, Inc. (“Bio-Matrix”) (ticker symbol BMSND), intending to rename Bio-Matrix as Rivulet Media. The comp
April 13, 2020	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers United States Securities And Exchange Commission Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2020 Bio-Matrix Scientific Group, Inc.
April 13, 2020	EX-2.1	Agreement and Plan of Merger by and among Bio-Matrix Scientific Group, Inc., Rivulet Films LLC, and Rivulet Films, Inc., dated April 8, 2020, incorporated by reference to Exhibit 2.1 of the Form 8-K filed on April 13, 2020. AGREEMENT AND PLAN OF MERGER by and among BIO-MATRIX SCIENTIFIC GROUP, INC., a Delaware corporation, RIVULET FILMS, INC., a Delaware corporation, and RIVULET FILMS LLC, an Arizona limited liability company Dated as of April 8, 2020 Article 1 DESCRIPTION OF TRANSACTION 1 1.1 MERGER OF MERGER SUB INTO THE COMPANY 1 1.2 EFFECT OF THE MERGER 1 1.3 CLOSING; EFFECTIVE TIME 1 1.4 CERTIFICATE OF INCORPORA
March 23, 2020	SC 14F1	BMSN / Bio-Matrix Scientific Group, Inc. SC 14F1 - - SC 14F1 UNITED STATE SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14F-1 Information Statement Required Pursuant to Section 14(f) of the Securities Exchange Act of 1934 and Rule 14f-1 Thereunder Bio-Matrix Scientific Group, Inc. (Exact Name of Registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-32201 (Commission File Number) 33-0824714 (
February 28, 2020	EX-10.2	Note Payable $2,039 PROMISSORY NOTE ("NOTE") - 10% SIMPLE INTEREST $ 2,039.48 12/12/2019 For VALUE RECEIVED, Pine Hills, Inc. ("Borrower'') promises to pay to BST Partners ("Lender'') the principal sum of $2,039.48 with accrued simple interest at the rate of 10% percent per annum on the balance. The said principal and accrued interest shall be payable in lawful money of the United States of America on December 12, 20
February 28, 2020	EX-10.4	Note Payable $1,236 PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST $ 1,236 01/29/2020 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc.
February 28, 2020	10-Q	BMSN / Bio-Matrix Scientific Group, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 bmsn013120form10q.htm FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Bio Matrix Scientific Group,
February 28, 2020	EX-10.1	Note Payable $6,000 PROMISSORY NOTE ("NOTE") - 10% SIMPLE INTEREST $ 6000 12/3/2019 For VALUE RECENED, Pine Hills, Inc.
February 28, 2020	EX-10.3	Note Payable $600 PROMISSORY NOTE ("NOTE") - 10% SIMPLE INTEREST $ 600 12/23/2019 For VALUE RECEIVED, Pine Hills, Inc.
January 29, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of
January 29, 2020	EX-3	Amendment to Certificate of Incorporation* Exhibit 3(i) STATE OF DELAWARE CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION OF BIO-MATRIX SCIENTIFIC GROUP, INC.
January 27, 2020	DEF 14C	BMSN / Bio-Matrix Scientific Group, Inc. DEF 14C - - DEF 14C SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 CHECK THE APPROPRIATE BOX: ☐ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)) ☒ Definitive Information Statement BIO-MATRIX SCIENTIFIC GROUP, INC.
January 15, 2020	PRE 14C	BMSN / Bio-Matrix Scientific Group, Inc. PRE 14C - - PRE 14C SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 CHECK THE APPROPRIATE BOX: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)) ☐ Definitive Information Statement BIO-MATRIX SCIENTIFIC GROUP, INC.
December 12, 2019	10-Q	BMSN / Bio-Matrix Scientific Group, Inc. 10-Q - Quarterly Report - FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Bio Matrix Scientific Group, Inc. (Exact name of small business iss
December 12, 2019	EX-10.4	Note Payable $100 PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST $100 8/29/2019 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc.
December 12, 2019	EX-10.3	Note Payable $10,000 PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST $10,000 8/22/2019 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc.
December 12, 2019	EX-10.2	Note Payable $62,00 PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST $6,200 10/8/ 2019 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc.
December 12, 2019	EX-10.1	Note Payable $1,000 PROMISSORY NOTE (“NOTE”) - 10% SIMPLE INTEREST $1,000 8/12/ 2019 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc.
November 13, 2019	10-12G/A	BMSN / Bio-Matrix Scientific Group, Inc. 10-12G/A - - FORM 10-12G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10/A Amendment No. 1 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Bio Matrix Scientific Group, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0824714 (State or other jurisdiction of incorporation or organization) (I.R.S. Emplo
November 13, 2019	CORRESP	BMSN / Bio-Matrix Scientific Group, Inc. CORRESP - - November 13, 2019 United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Ms.
November 13, 2019	CORRESP	BMSN / Bio-Matrix Scientific Group, Inc. CORRESP - - CORRESP 1 filename1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10/A Amendment No. 1 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Bio Matrix Scientific Group, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0824714 (State or other jurisdiction of incorporation or org
October 15, 2019	EX-3.III	Amendment to Certificate of Incorporation Exhibit 3(iii) STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION The corporation organized and existing under and by virtue of the General Corporation law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Bio-Matrix Scientific Group, Inc.
October 15, 2019	EX-3.VIII	BIO-MATRIX SCIENTIFIC GROUP, INC. GENERAL BY-LAWS AMENDED AND RESTATED AS OF January 1, 2019 AMENDED AND RESTATED BY-LAWS OF BIO-MATRIX SCIENTIFIC GROUP, INC. ARTICLE I EX-3.VIII 9 ex3viii.htm EXHIBIT 3(VIII) EXHIBIT 3(viii) BIO-MATRIX SCIENTIFIC GROUP, INC. GENERAL BY-LAWS AMENDED AND RESTATED AS OF January 1, 2019 AMENDED AND RESTATED BY-LAWS OF BIO-MATRIX SCIENTIFIC GROUP, INC. ARTICLE I OFFICES Section 1. Offices. The Corporation may have offices at such places, both within and without the State of Delaware, as the Board of Directors may from time to time det
October 15, 2019	EX-3.IV	BIO-MATRIX SCIENTIFIC GROUP, INC. GENERAL BY-LAWS AMENDED AND RESTATED AS OF January 1, 2019 AMENDED AND RESTATED BY-LAWS OF BIO-MATRIX SCIENTIFIC GROUP, INC. ARTICLE I EXHIBIT 3(iv) BIO-MATRIX SCIENTIFIC GROUP, INC. GENERAL BY-LAWS AMENDED AND RESTATED AS OF January 1, 2019 AMENDED AND RESTATED BY-LAWS OF BIO-MATRIX SCIENTIFIC GROUP, INC. ARTICLE I OFFICES Section 1. Offices. The Corporation may have offices at such places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the Corporation
October 15, 2019	EX-10.1	Stock Purchase Agreement Purchase of Pine Hills Inc EXHIBIT 10.1 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the "Agreement") is entered into and is effective on this I 8 th day of June, 2019 by and between Bio-Matrix Scientific Group, Inc. (the "Buyer"), a Delaware corporation with principal address at 4700 Spring Street, Suite 304, La Mesa, California, 91942 and Heather Cassady, (the "Seller") the owner of 1,000 common shares of Pine
October 15, 2019	EX-3.II	Amendment to Certificate of Incorporation Exhibit 3(ii) CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF TASCO HOLDINGS INTERNATIONAL, INC.
October 15, 2019	EX-10.2	Line of Credit Note Payable David Koos Exhibit 10.2 LINE OF CREDIT PROMISSORY NOTE $500,000 Date: October 1, 2008 FOR VALUE RECEIVED, Bio Matrix Scientific Group, Inc., ("Borrower") promises to pay to the order of David Koos. ("Lender"), a Nevada Corporation, the principal sum of Five Hundred Thousand Dollars ($500,000), or so much thereof as may be disbursed to, or for the benefit of the Borrower by Lender in Lender's sole and absolut
October 15, 2019	EX-10.3	Forgiveness Letter David Koos Exhibit 10.3 To: Bio-Matrix Scientific Group, Inc. From: David R Koos Date: Nov 1, 2016 I hereby forgive all accrued interest on amounts lent by me to Bio-Matrix Scientific Group, Inc. I may lend further amounts at my discretion (“Further Amounts”). Further Amounts shall accrue no interest and shall be payable upon my demand. Sincerely, /s/ David Koos David R. Koos
October 15, 2019	EX-3.V	Certificate of Designation Series B Exhibit 3(v) CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B PREFERRED STOCK OF BIO MATRIX SCIENTIFIC GROUP, INC.
October 15, 2019	EX-10.4	Blackbriar Note 15000 Exhibit 10.4 PROMISSORY NOTE ("NOTE"} -10% SIMPLE INTEREST $15,000.00 July 25, 2016 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc. ("Borrower") promises to pay to Blackbriar Partners Inc. ("Lender") the principal sum of Fifteen Thousand Dollars ($15,000.00) with accrued simple interest at the rate of 10% percent per annum on the balance. The said principal and accrued interest shall be paya
October 15, 2019	EX-10.5	Blackbriar Note 5000 Exhibit 105 PROMISSORY NOTE ("NOTE”) - 10% SIMPLE INTEREST $5,000.00 April 8, 2016 For VALUE RECEIVED, Bio Matrix Scientific Group, Inc. ("Borrower") promises to pay to Blackbriar Partners, Inc. ("Lender") the principal sum of Five Thousand Dollars [$5,000] with accrued simple interest at the rate of 10% percent per annum on the balance. Principal and accrued interest shall be due and payable to t
October 15, 2019	10-12G	BMSN / Bio-Matrix Scientific Group, Inc. 10-12G - - 10-12G 10-12G 1 bmsn100719form10.htm 10-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 Bio Matrix Scientific Group, Inc. (Exact name of registrant as specified in its charter) Delaware 33-0824714 (State or other jurisdiction of incorporation or organiza
October 15, 2019	EX-10.6	Forgiveness Letter Blackbriar Exhibit 10.6 To: Bio-Matrix Scientific Group, Inc. From: Blackbriar Partners Date: Nov 1, 2016 Blackbriar Partners (“BB”) hereby forgives all accrued interest on amounts lent by BB to Bio-Matrix Scientific Group, Inc. BB may lend further amounts at my discretion (“Further Amounts”). Further Amounts shall accrue no interest and shall be playable upon BB’s demand. Sincerely, /s/ David Koos David R.
October 15, 2019	EX-14	Code of Ethics Exhibit 14 POLICY ON ETHICS AND BUSINESS CONDUCT Tasco Holdings International, Inc.
October 15, 2019	EX-3.I	Certificate of Incorporation Exhibit 3(i) CERTIFICATE OF INCORPORATION OF TASCO INTERNATIONAL, INC. FIRST. The name of this corporation shall be: TASCO INTERNATIONAL, INC. SECOND. It's registered office in the State of Delaware is to be located at 1013 Centre Road, in the City of Wilmington, County of New Castle, 19805, and its registered agent at such address is THE COMPANY CORPORATION. THIRD. The purpose or purposes of the
October 15, 2019	EX-3.VI	Certificate of Designation Series AA Exhibit 3(vi) CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES AA PREFERRED STOCK OF BIO MATRIX SCIENTIFIC GROUP, INC.
October 15, 2019	EX-3.VII	Certificate of Designation Series AAA EX-3.VII 8 ex3vii.htm EXHIBIT 3(VII) EXHIBIT 3(vii) CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES AAA PREFERRED STOCK OF BIO-MATRIX SCIENTIFIC GROUP, INC. A Delaware Corporation PURSUANT TO SECTION 151 OF THE GENERAL CORPORATION LAW OF THE STATE OF DELAWARE The undersigned, DAVID R. KOOS, does hereby certify that: 1. He is the President and Secretary of BIO-MATRIX SCI
October 15, 2019	EX-4.1	Form of Certificate Common stock Exhibit 4.1
February 6, 2017	15-12G	Bio-Matrix Scientific Group FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 0-32201 BIO-MATRIX SCIENTIFIC GROUP, INC. (Exact name of registrant as spec
January 20, 2017	EX-3.I	CERTIFICATE OF DESIGNATIONS OF THE SERIES M PREFERRED STOCK REGEN BIOPHARMA, INC. (PURSUANT TO NRS 78.1955) Exhibit 3(i) CERTIFICATE OF DESIGNATIONS OF THE SERIES M PREFERRED STOCK OF REGEN BIOPHARMA, INC.
January 20, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of
December 27, 2016	10-K	Bio-Matrix Scientific Group FORM 10-K (Annual Report) United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission file number: 0-32201 BIO-MATRIX SCIENTIFIC GROUP, INC. (N
December 27, 2016	EX-10.95	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.94	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.97	CONVERTIBLE PROMISSORY NOTE Exhibit 10.97 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF
December 27, 2016	EX-10.93	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.92	Agreement made this 5 Agreement made this 5th day of August 2016 by and between Regen Bioparma, Inc. (“Company) and David R. Koos (“Koos”) WHEREAS, On February 13, 2015 Koos was issued Nine Million of the Company’s Common Shares (“Compensation Common Shares”) pursuant to that employment agreement entered into by and between Koos and the Company on February 11, 2015 ( “Employment Agreement”) WHEREAS , on March 17, 2015
December 27, 2016	EX-10.105	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.100	CONVERTIBLE PROMISSORY NOTE EX-10.100 16 ex10100.htm EXHIBIT 10.100 Exhibit 10.99 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR
December 27, 2016	EX-10.96	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who EX-10.96 6 ex1096.htm EXHIBIT 10.96 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms
December 27, 2016	EX-10.107	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.98	CONVERTIBLE PROMISSORY NOTE EX-10.98 14 ex1098.htm EXHIBIT 10.98 Exhibit 10.98 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OT
December 27, 2016	EX-10.99	CONVERTIBLE PROMISSORY NOTE Exhibit 10.99 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF
December 27, 2016	EX-10.106	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.102	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.101	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.104	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc.
December 27, 2016	EX-10.103	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who EX-10.103 19 ex10103.htm EXHIBIT 10.103 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the t
October 24, 2016	EX-16.1	October 20, 2016 October 20, 2016 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.
October 24, 2016	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of
August 8, 2016	10-Q/A	Bio-Matrix Scientific Group FORM 10-Q/A (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended June 30, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP, IN
August 8, 2016	EX-10.6	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.6 THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in accordance with the terms and conditions set for
August 8, 2016	EX-10.3	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who EX-10.3 4 ex103.htm EXHIBIT 10.3 Exhibit 10.3 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with
August 8, 2016	EX-10.2	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.2 THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in accordance with the terms and conditions set for
August 8, 2016	EX-10.5	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.5 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set for
August 8, 2016	EX-10.1	CONVERTIBLE PROMISSORY NOTE EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWI
August 8, 2016	10-Q	Bio-Matrix Scientific Group FORM 10-Q (Quarterly Report) ECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended June 30, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP, INC. (Exact name of r
August 8, 2016	EX-10.4	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.4 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set for
July 7, 2016	EX-10.1	INDEMNIFICATION AGREEMENT Exhibit 10.1 July 1, 2016 David Koos Chairman & CEO Regen BioPharma Inc. (RGBP) 4700 Spring St., #304 La Mesa, CA 91942 Delivered: 07/01/2016 Via email to: David Koos [email protected] Dear David, The purpose of this investment banking engagement agreement (the "Agreement") is to set forth the terms and conditions pursuant to which CIM Securities, LLC ("CIM"), a FINRA member in good st
July 7, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of Inco
June 8, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of Inco
June 8, 2016	EX-10.1	ENGAGEMENT AGREEMENT Exhibit 10.1 ENGAGEMENT AGREEMENT CONFIDENTIAL May 26, 2016 David R. Koos, Ph.D., DBA Chairman & Chief Executive Officer Regen Biopharma, Inc. 4700 Spring Street Suite 304 La Mesa, CA 91942 RE: Engagement of Objective Capital Partners Dr. Koos, We are pleased that you wish to retain Objective Capital Partners as your exclusive investment banker in connection with the possible Strategic Development
May 10, 2016	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of Inco
May 9, 2016	EX-10.1	CONVERTIBLE PROMISSORY NOTE EX-10.1 8 ex101.htm EXHIBIT 10.1 Exhibit 10.1 CONVERTIBLE PROMISSORY NOTE THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWI
May 7, 2016	10-Q	Bio-Matrix Scientific Group FORM 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended March 31, 2016 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP, INC. (Exact name of
April 29, 2016	10-Q/A	Bio-Matrix Scientific Group FORM 10-Q/A (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 3 ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP
April 29, 2016	10-K/A	Bio-Matrix Scientific Group FORM 10-K/A (Annual Report) 10-K/A 1 bmsn093015form10ka.htm FORM 10-K/A United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K / A Amendment No. 4 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Comm
April 29, 2016	CORRESP	United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K / A Amendment No. 4 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ☐ TRANSITION REPORT United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K / A Amendment No. 4 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission file number: 0-32201 BIO-MATRIX SCIEN
April 29, 2016	CORRESP	April 25, 2016 April 25, 2016 United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Mr.
April 29, 2016	CORRESP	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 3 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ☐ TRANSITION REPORT UNDER SECT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 3 ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP
April 20, 2016	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of In
April 15, 2016	10-Q/A	Bio-Matrix Scientific Group FORM 10-Q/A (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 2 ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP
April 15, 2016	10-K/A	Bio-Matrix Scientific Group FORM 10-K/A (Annual Report) United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K/A Amendment No. 3 ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission file number: 0-32201 BIO-MATRIX SCIENTI
April 15, 2016	CORRESP	Bio-Matrix Scientific Group ESP April 12, 2016 United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Mr.
April 9, 2016	EX-10.2	WHEREAS, Regen Biopharma, Inc. (the ?Company?) wishes to reward and compensate Harry Lander PhD (?Employee) for Employee?s efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to th Exhibit 10.2 WHEREAS, Regen Biopharma, Inc. (the ?Company?) wishes to reward and compensate Harry Lander PhD (?Employee) for Employee?s efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the Company?s Investigational New Drug Application for HemaXellerate. WHEREAS, Employee?s efforts have resulted in securing the consent of
April 9, 2016	EX-10.1	WHEREAS, Regen Biopharma, Inc. (the “Company”) wishes to reward and compensate David Koos (“Employee) for Employee’s efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the Comp Exhibit 10.1 WHEREAS, Regen Biopharma, Inc. (the ?Company?) wishes to reward and compensate David Koos (?Employee) for Employee?s efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the Company?s Investigational New Drug Application for HemaXellerate. WHEREAS, Employee?s efforts have resulted in securing the consent of the FD
April 9, 2016	EX-10.3	WHEREAS, Regen Biopharma, Inc. (the “Company”) wishes to reward and compensate Todd Caven (“Employee) for Employee’s efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the Comp EX-10.3 4 ex103.htm EXHIBIT 10.3 Exhibit 10.3 WHEREAS, Regen Biopharma, Inc. (the “Company”) wishes to reward and compensate Todd Caven (“Employee) for Employee’s efforts in addressing all clinical hold issues identified by the United States Food and Drug Administration (FDA) related to the Company’s Investigational New Drug Application for HemaXellerate. WHEREAS, Employee’s efforts have resulted
April 9, 2016	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of Inc
April 9, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of
April 9, 2016	EX-10.1	OPEN INNOVATION DRUG DISCOVERY PROGRAM AND MATERIAL TRANSFER AGREEMENT Exhibit 10.1 OPEN INNOVATION DRUG DISCOVERY PROGRAM AND MATERIAL TRANSFER AGREEMENT This Open Innovation Drug Discovery Program and Material Transfer Agreement (the ?Program Agreement?) is effective on the date of last signature of the parties who agree to the following terms and conditions. I. PARTIES The parties to this Program Agreement are: Eli Lilly and Company and its affiliates, having its
March 24, 2016	EX-10.2	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.2 THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in accordance with the terms and conditions set for
March 24, 2016	EX-10.1	THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( ?Purchaser?), a _______ who Exhibit 10.1 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set for
March 24, 2016	EX-10.4	THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( ?Purchaser?), a _______ who EXHIBIT 10.4 THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in accordance with the terms and conditions set for
March 24, 2016	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2016 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of
March 24, 2016	EX-10.3	THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( ?Purchaser?), a _______ who Exhibit 10.3 THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in accordance with the terms and conditions set for
March 22, 2016	10-K/A	Bio-Matrix Scientific Group FORM 10-K/A (Annual Report) United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K/A Amendment No. 2 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commision File Number: 000-32201 BIO-MATRIX SCIENTIFIC GROUP, INC. (Name of small busin
March 22, 2016	CORRESP	Bio-Matrix Scientific Group ESP March 20, 2016 United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Mr.
March 22, 2016	10-Q/A	Bio-Matrix Scientific Group FORM 10-Q/A (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MATRIX SCIENTIFIC GROUP
February 2, 2016	10-Q	BMSN / Bio-Matrix Scientific Group, Inc. 10-Q - Quarterly Report - FORM 10-Q 10-Q 1 bmsn123115form10q.htm FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the quarterly period ended December 31, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from to . Commission File Number 0-32201 BIO-MA
January 8, 2016	10-K	BMSN / Bio-Matrix Scientific Group, Inc. 10-K - Annual Report - FORM 10-K United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . BIO-MATRIX SCIENTIFIC GROUP, INC. (Name of small business issuer in i
January 8, 2016	10-K/A	BMSN / Bio-Matrix Scientific Group, Inc. 10-K/A - Annual Report - FORM 10-K/A United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K/A Amendment No. 1 ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ending September 30, 2015 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commision File Number: 000-32201 BIO-MATRIX SCIENTIFIC GROUP, INC. (Name of small busin
January 8, 2016	EX-10.55	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.55 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set fo
January 8, 2016	EX-10.54	THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and __________( “Purchaser”), a _______ who Exhibit 10.54 THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in accordance with the terms and conditions set fo
December 30, 2015	NT 10-K	Bio-Matrix Scientific Group FORM NT 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For period ended: September 30 , 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Tran
December 17, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2015 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of
December 17, 2015	EX-10.1	RESEARCH COLLABORATION AGREEMENT EX-10.1 2 ex101.htm EXHIBIT 10.1 Exhibit 10.1 RESEARCH COLLABORATION AGREEMENT This Agreement is between the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services, having offices located at 9800 Medical Center Drive, Rockville, MD 20850, and Regen Biopharma, In
December 15, 2015	8-K	Other Events 8-K 1 bmsn121415form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2015 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-082
November 24, 2015	EX-10.5	UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. Exhibit 10.5 UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in ac
November 24, 2015	EX-10.8	October 14, 2014 EX-10.8 8 ex108.htm EXHIBIT 10.8 Exhibit 10.8 October 14, 2014 Francesco Marincola, MD Chief Research Officer Sidra Medical and Research Center Doha, Quatar Dear Dr. Marincola Thank you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may unde
November 24, 2015	EX-10.10	August 4, 2015 EX-10.10 10 ex1010.htm EXHIBIT 10.10 Exhibit 10.10 August 4, 2015 Dear Jonathan This letter is a follow up to our previous discussion about the Scientific Advisory Board for Regen BioPharma, Inc. The function of the Scientific Advisory Board is to review research directions that Regen BioPharma, Inc. may undertake, determining those projects which may lead to future developments/advancements in th
November 24, 2015	EX-10.4	UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. Exhibit 10.4 UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in ac
November 24, 2015	EX-10.1	UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. Exhibit 10.1 UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. THIS UNIT PURCHASE AGREEMENT (the “Agreement”) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the “Company”) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( “Purchaser”), a whose address is . WHEREAS: The Purchaser desires to purchase units (“Units”) of securities of the Company in ac
November 24, 2015	EX-10.7	October 14, 2015 Exhibit 10.7 October 14, 2015 Stefano Bertuzzi, Ph.D. American Society for Cell biology 8120 Woodmont Avenue, Suite 750 Bethesda MD 20814-2762 Dear Dr. Bertuzzi Thank you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help
November 24, 2015	EX-10.2	UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. Exhibit 10.2 UNIT PURCHASE AGREEMENT REGEN BIOPHARMA, INC. THIS UNIT PURCHASE AGREEMENT (the ?Agreement?) is entered into by and among Regen Biopharma, Inc., a Nevada corporation (the ?Company?) whose address is 4700 Spring Street, St 304, La Mesa, California 91942 and ( ?Purchaser?), a whose address is . WHEREAS: The Purchaser desires to purchase units (?Units?) of securities of the Company in ac
November 24, 2015	EX-10.6	Lorraine J Gudas Exhibit 10.6 Lorraine J Gudas Chairman Department of Pharmacology Weill Cornell medical College 1300 York Avenue New York, NY 10021 Dear Dr. Gudas Thank you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those
November 24, 2015	EX-10.9	November 13, 2015 Exhibit 10.9 November 13, 2015 Ralph L. Nachman, MD Weill Cornell Medical College 1300 York Avenue New York NY 10021 Dear Dr. Nachman Thank you so much for your willingness to join the Scientific Advisory Board of Regen Biopharma Inc. the function of the Scientific Advisory Board is to review research strategy and projects that Regen Biopharma Inc.may undertake and help identify those projects whi
November 24, 2015	8-K	Financial Statements and Exhibits, Other Events NITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2015 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of In
November 5, 2015	EX-17.1	David Koos Exhibit 17.1 David Koos Chairman and Chief Executive Officer Regen Biopharma 4700 Spring Street La Mesa October 30, 2015 Dear Dr. Koos Please consider this letter my formal resignation from position of Chief Scientific Officer and Board Member of Regen Biopharma due to health reasons. /s/ Thomas Ichim Thomas Ichim
November 5, 2015	EX-10.1	AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND THOMAS ICHIM Exhibit 10.1 AGREEMENT BY AND BETWEEN REGEN BIOPHARMA, INC. AND THOMAS ICHIM Agreement made on November 2. 2015 by and between Thomas Ichim (“Consultant”) , a natural person whose address is at 9255 Towne Centre Drive #450 San Diego CA 91211 and Regen Biopharma, Inc. (“Company”) , a Nevada corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company ma
November 5, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2015 Bio-Matrix Scientific Group, Inc. (Exact Name of Company as Specified in Charter) Commission File Number: 0-32201 Delaware 33-0824714 (State or Other Jurisdiction of

RIVU / Rivulet Media Inc - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)